Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: The state of the art

Sean R. Williamson, Rodolfo Montironi, Antonio Lopez-Beltran, Gregory T. MacLennan, Darrell Davidson, Liang Cheng

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Urothelial carcinoma in situ (CIS) is regarded as a precursor of invasive bladder carcinoma. Although relatively uncommon as a primary entity, CIS is frequently seen in conjunction with other bladder tumors and represents a significant source of difficulty for surveillance of patients with known bladder cancer. CIS lesions are difficult to detect by cystoscopic examination or by currently available screening markers. Urothelial CIS is infrequently reported in the literature as a primary process; however, a wide variety of emerging methodologies are becoming available for screening and follow-up of bladder cancer. Most new methods demonstrate sensitivity and specificity similar to the current standard of urine cytology and cystoscopy. Detection of high-grade lesions such as CIS by these methods appears generally better than detection of low-grade lesions. Current molecular evidence suggests that a spectrum of genetic aberrations including p53 mutations are strongly associated with the potentially invasive CIS phenotype in contrast to low-grade papillary and hyperplastic lesions. These low-grade lesions frequently recur but infrequently become invasive. Patients with high-grade lesions including CIS and high-grade papillary tumors warrant aggressive treatment and life-long surveillance.

Original languageEnglish
Pages (from-to)112-126
Number of pages15
JournalCritical Reviews in Oncology/Hematology
Volume76
Issue number2
DOIs
StatePublished - Nov 2010

Fingerprint

Carcinoma in Situ
Urinary Bladder
Urinary Bladder Neoplasms
Therapeutics
Cystoscopy
Cell Biology
Urine
Carcinoma
Phenotype
Sensitivity and Specificity
Mutation
Neoplasms

Keywords

  • Bladder
  • Molecular pathogenesis
  • Urothelial carcinoma in situ
  • Urothelial dysplasia

ASJC Scopus subject areas

  • Oncology
  • Hematology
  • Geriatrics and Gerontology

Cite this

Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder : The state of the art. / Williamson, Sean R.; Montironi, Rodolfo; Lopez-Beltran, Antonio; MacLennan, Gregory T.; Davidson, Darrell; Cheng, Liang.

In: Critical Reviews in Oncology/Hematology, Vol. 76, No. 2, 11.2010, p. 112-126.

Research output: Contribution to journalArticle

Williamson, Sean R. ; Montironi, Rodolfo ; Lopez-Beltran, Antonio ; MacLennan, Gregory T. ; Davidson, Darrell ; Cheng, Liang. / Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder : The state of the art. In: Critical Reviews in Oncology/Hematology. 2010 ; Vol. 76, No. 2. pp. 112-126.
@article{2ffb2c685340432598b286366fc5737f,
title = "Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder: The state of the art",
abstract = "Urothelial carcinoma in situ (CIS) is regarded as a precursor of invasive bladder carcinoma. Although relatively uncommon as a primary entity, CIS is frequently seen in conjunction with other bladder tumors and represents a significant source of difficulty for surveillance of patients with known bladder cancer. CIS lesions are difficult to detect by cystoscopic examination or by currently available screening markers. Urothelial CIS is infrequently reported in the literature as a primary process; however, a wide variety of emerging methodologies are becoming available for screening and follow-up of bladder cancer. Most new methods demonstrate sensitivity and specificity similar to the current standard of urine cytology and cystoscopy. Detection of high-grade lesions such as CIS by these methods appears generally better than detection of low-grade lesions. Current molecular evidence suggests that a spectrum of genetic aberrations including p53 mutations are strongly associated with the potentially invasive CIS phenotype in contrast to low-grade papillary and hyperplastic lesions. These low-grade lesions frequently recur but infrequently become invasive. Patients with high-grade lesions including CIS and high-grade papillary tumors warrant aggressive treatment and life-long surveillance.",
keywords = "Bladder, Molecular pathogenesis, Urothelial carcinoma in situ, Urothelial dysplasia",
author = "Williamson, {Sean R.} and Rodolfo Montironi and Antonio Lopez-Beltran and MacLennan, {Gregory T.} and Darrell Davidson and Liang Cheng",
year = "2010",
month = "11",
doi = "10.1016/j.critrevonc.2010.01.005",
language = "English",
volume = "76",
pages = "112--126",
journal = "Critical Reviews in Oncology/Hematology",
issn = "1040-8428",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Diagnosis, evaluation and treatment of carcinoma in situ of the urinary bladder

T2 - The state of the art

AU - Williamson, Sean R.

AU - Montironi, Rodolfo

AU - Lopez-Beltran, Antonio

AU - MacLennan, Gregory T.

AU - Davidson, Darrell

AU - Cheng, Liang

PY - 2010/11

Y1 - 2010/11

N2 - Urothelial carcinoma in situ (CIS) is regarded as a precursor of invasive bladder carcinoma. Although relatively uncommon as a primary entity, CIS is frequently seen in conjunction with other bladder tumors and represents a significant source of difficulty for surveillance of patients with known bladder cancer. CIS lesions are difficult to detect by cystoscopic examination or by currently available screening markers. Urothelial CIS is infrequently reported in the literature as a primary process; however, a wide variety of emerging methodologies are becoming available for screening and follow-up of bladder cancer. Most new methods demonstrate sensitivity and specificity similar to the current standard of urine cytology and cystoscopy. Detection of high-grade lesions such as CIS by these methods appears generally better than detection of low-grade lesions. Current molecular evidence suggests that a spectrum of genetic aberrations including p53 mutations are strongly associated with the potentially invasive CIS phenotype in contrast to low-grade papillary and hyperplastic lesions. These low-grade lesions frequently recur but infrequently become invasive. Patients with high-grade lesions including CIS and high-grade papillary tumors warrant aggressive treatment and life-long surveillance.

AB - Urothelial carcinoma in situ (CIS) is regarded as a precursor of invasive bladder carcinoma. Although relatively uncommon as a primary entity, CIS is frequently seen in conjunction with other bladder tumors and represents a significant source of difficulty for surveillance of patients with known bladder cancer. CIS lesions are difficult to detect by cystoscopic examination or by currently available screening markers. Urothelial CIS is infrequently reported in the literature as a primary process; however, a wide variety of emerging methodologies are becoming available for screening and follow-up of bladder cancer. Most new methods demonstrate sensitivity and specificity similar to the current standard of urine cytology and cystoscopy. Detection of high-grade lesions such as CIS by these methods appears generally better than detection of low-grade lesions. Current molecular evidence suggests that a spectrum of genetic aberrations including p53 mutations are strongly associated with the potentially invasive CIS phenotype in contrast to low-grade papillary and hyperplastic lesions. These low-grade lesions frequently recur but infrequently become invasive. Patients with high-grade lesions including CIS and high-grade papillary tumors warrant aggressive treatment and life-long surveillance.

KW - Bladder

KW - Molecular pathogenesis

KW - Urothelial carcinoma in situ

KW - Urothelial dysplasia

UR - http://www.scopus.com/inward/record.url?scp=77957200237&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77957200237&partnerID=8YFLogxK

U2 - 10.1016/j.critrevonc.2010.01.005

DO - 10.1016/j.critrevonc.2010.01.005

M3 - Article

C2 - 20097572

AN - SCOPUS:77957200237

VL - 76

SP - 112

EP - 126

JO - Critical Reviews in Oncology/Hematology

JF - Critical Reviews in Oncology/Hematology

SN - 1040-8428

IS - 2

ER -